Biotech Patentable Subject Matter After Bilski

BIOTECH Patentable Subject Matter Post Bilski

Patentable Subject Matter: 35 U.S.C. § 101 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

§ 101 Eligible Inventions (Discoveries) ,[object Object],[object Object],[object Object],[object Object],[object Object]

But Exclusive of (via stare decisis ): ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Rationales For Exclusions ,[object Object],[object Object],[object Object],[object Object]

BIOTECH PATENTS ,[object Object],[object Object],[object Object]

Post Chakrabarty 35 USC § 101 Was Boring For Biotech Until: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Lab. Corp. v Metabolite Labs (Diagnostic Patent) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SCOTUS: Lab. Corp. v Metabolite ,[object Object],[object Object],[object Object],[object Object],[object Object]

Bilski: Claim 1 (paraphrased) steps ,[object Object],[object Object],[object Object],[object Object]

Bilski: Prosecution and Court History ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Legal Theories For Non-patentable Claims Before SCOTUS ,[object Object],[object Object],[object Object]

SCOTUS: MOT Not The Standard ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Claims A Process (Business Method) ,[object Object],[object Object],[object Object]

SCOTUS Affirms: Not Patentable ,[object Object],[object Object],[object Object],[object Object],[object Object]

Effects of Bilski on Biotech ,[object Object],[object Object]

Prometheus Labs v Mayo ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Why Was Prometheus Remanded? ,[object Object],[object Object],[object Object],[object Object],[object Object]

CAFC Reaffirms Previous Decision ,[object Object],[object Object],[object Object],[object Object]

Classen Immunotherapies v Biogen IDEC ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

King Pharmaceuticals v Eon Labs Post SCOTUS Bilski Decision ,[object Object],[object Object],[object Object],[object Object]

Association for Molecular Pathology v USPTO and Myriad (Gene patents) ,[object Object],[object Object],[object Object],[object Object],[object Object]

AMP’s Legal Theory ,[object Object],[object Object],[object Object]

Court Recognized Issues ,[object Object],[object Object]

Court Traversed “Different In Character” ,[object Object],[object Object],[object Object]

Court Finds All Claims Invalid ,[object Object],[object Object],[object Object]

How Will Higher Courts Decide? ,[object Object],[object Object],[object Object]

Dyk’s Comments ,[object Object],[object Object],[object Object]

How Will Higher Courts Decide? ,[object Object],[object Object],[object Object],[object Object]

Practice For Embracing & Mitigating Uncertainty ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Biotech Patentable Subject Matter After Bilski

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Ähnlich wie Biotech Patentable Subject Matter After Bilski

Ähnlich wie Biotech Patentable Subject Matter After Bilski (20)

Biotech Patentable Subject Matter After Bilski